Key Takeaways
Trian Fund Management has taken a nearly 5 percent stake in Solventum Corp. and is demanding three major changes to address what it calls significant mismanagement since the company’s spin-off from 3M.
"Solventum's spin-out has been managed in a way that has maximized executive compensation, not shareholder value," Trian said in an open letter published Wednesday. The firm noted it has heard from several large shareholders who have expressed their frustration with the company.
The activist investor highlighted that Solventum’s market capitalization is approximately $12 billion, a steep drop from the $25 billion analysts had projected at its separation, erasing $13 billion in shareholder value. In contrast, Trian noted the CEO has received more than $80 million in compensation in just over two years. Shares of Solventum rose 1.7 percent on the news.
Trian, founded by Nelson Peltz, outlined a three-point plan to improve performance. The firm is calling on Solventum to right-size overhead costs, simplify its portfolio by divesting non-core businesses, starting with the immediate separation of the Health Information Systems business, and to improve capital allocation by prioritizing share repurchases.
The investment firm stated it had attempted to engage constructively with Solventum’s board but said the company has not taken action to drive value or add independent shareholder representation. Solventum's stock is down 16 percent year-to-date, trading near its 52-week low, according to data from InvestingPro.
Trian's public pressure places the board in a difficult position, forcing it to either adopt the activist's suggestions or publicly defend its current strategy. This campaign could lead to a proxy fight if the board does not acquiesce, creating further volatility for a stock that has yet to deliver returns for its shareholders.
This article is for informational purposes only and does not constitute investment advice.
